Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 September 2024
Diabetic retinopathy: management and monitoring (NG242)Product type:GuidanceProgramme:NICE guidelinePublished: 13 August 2024
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Type 2 diabetes in adults: management (medicines update)Status:In developmentProgramme:NICE guidelineExpected publication date: 30 July 2025
Ranibizumab port delivery system for treating diabetic macular oedema ID6137Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin icodec for treating type 2 diabetes [ID6175]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cardiometabolic disease prevention and treatment guidelinesStatus:In developmentProgramme:NICE HubExpected publication date: TBC
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC